Patents by Inventor Francisco J. Silva

Francisco J. Silva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8778679
    Abstract: Human umbilical cord lining stem cells that are capable of differentiating into cells of the mesodermal lineage and ectodermal lineage are described, as well as methods of isolating, expanding, culturing, and cryopreserving such cells.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: July 15, 2014
    Assignee: DaVinci Biosciences LLC
    Inventors: Francisco J. Silva, Rafael Gonzalez
  • Patent number: 8119398
    Abstract: Compositions and methods for promoting tissue regeneration, particularly skin regeneration, with adipose-derived stem cells are provided. Additionally methods and compositions for promoting tissue regeneration with adipose-derived stem cell side population cells are provided. The adipose-derived cells are administered in a tissue regenerating effect amount optionally with a bioactive agent. Additionally the adipose derived cells can be autologous or syngeneic.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: February 21, 2012
    Assignee: PrimeGen Biotech LLC
    Inventors: Chauncey B. Sayre, Francisco J. Silva
  • Publication number: 20110008764
    Abstract: Adult human gonadal stem cells that are capable of differentiating into cells of the mesodermal lineage and ectodermal lineage are described.
    Type: Application
    Filed: June 2, 2010
    Publication date: January 13, 2011
    Applicant: DAVINCI BIOSCIENCES LLC
    Inventors: Francisco J. Silva, Rafael Gonzalez
  • Publication number: 20090263357
    Abstract: Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy and have the potential to differentiate into more committed cell lineages. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cellular regenerative therapy are provided.
    Type: Application
    Filed: January 11, 2008
    Publication date: October 22, 2009
    Applicant: PrimeGen Biotech, LLC
    Inventors: Chauncey B. Sayre, Francisco J. Silva